Unichem Labs share price: Unichem Laboratories' board has approved asset purchase agreement with Bayshore Pharmaceuticals
Ipca shares ended the day's trade at Rs 898 apiece, down 1.6 per cent on BSE
Ipca Laboratories on Wednesday said it has completed the acquisition of a 33.38 per cent stake in Unichem for Rs 945.35 crore. Last week, Ipca got approval from the Competition Commission of India (CCI) for a 59.38 per cent stake purchase in listed Unichem Laboratories. "Post receipt of approval of CCI, the company has acquired 2,35,01,440 fully paid-up equity shares of Rs 2 each, constituting about 33.38 per cent of the paid-up equity share capital of Unichem Laboratories from one of Unichem's promoter shareholders, at a price of Rs 402.25 per equity share aggregating to Rs 945.35 crore," Ipca said in a regulatory filing. The deal was executed through a block deal on the National Stock Exchange (NSE), it added. Ipca has already made an open offer to Unichem's shareholders to acquire another 26 per cent of the fully diluted outstanding equity share capital of the company at a price of Rs 440 per share, aggregating to Rs 805.44 crore. The Draft Letter of Offer (DLOF) for the open o
Competition Commission on Thursday said it has approved Ipca Laboratories' proposed 59.38 per cent stake purchase in Unichem Laboratories. The proposed deal involves the company buying 33.38 per cent shareholding in Unichem Laboratories pursuant to a share purchase agreement. Further, Ipca Laboratories has to make an open offer to buy an additional 26 per cent stake in listed Unichem Laboratories under Sebi norms. In a release, the Competition Commission of India (CCI) said the Ipca Laboratories will acquire up to 59.38 per cent stake in the target company. The deal has been cleared by the regulator, as per the release. Deals beyond a certain threshold require the approval of CCI, which keeps a tab on unfair business practices in the marketplace.
Unichem's facilities are compliant with US regulations, but it posted losses for nine months of FY23
The shares will be purchased at the cost of Rs 440 per share post the approval from the Competition Commission of India under the Competition Act, 2002
The broader markets also weakened towards the end of the trade, and the BSE Midcap and Smallcap indices ended with a loss of 1.4 per cent each
Aripiprazole tablets are indicated for Schizophrenia and Irritability associated with Autistic Disorder
Drug firm Unichem Laboratories on Thursday said it has received approval from the US health regulator to market generic Amitriptyline HCl tablets used in the treatment of depression. The company has received abbreviated new drug application (ANDA) approval to market its Amitriptyline HCl tablets USP, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg from the United States Food and Drug Administration (USFDA), Unichem Laboratories said in a regulatory filing. The product is a generic version of AstraZeneca Pharmaceuticals LP's Elavil tablets in the same strengths, it added. The tablets will be commercialised from the company's Goa plant, Unichem Labs said. Amitriptyline HCl Tablets are indicated for the relief of symptoms of depression, it added. Shares of Unichem Laboratories closed at Rs 358.60 per scrip on BSE, up 7.43 per cent from its previous close.
Drug firmUnichem Laboratories on Wednesday said it has received approval from the US health regulator to market its generic Celecoxib capsules
Unichem Lab stock had hit a 52-week high of Rs 200.60 on the BSE on May 24, 2019, while its 52-week low was Rs 75.10, hit on March 23 this year.
The company's tablets are a generic version of Bristol-Myers Squibb Company's Buspar tablets in the same strengths
Unichem said the product will be commercialised from its Ghaziabad plant
Unichem Laboratories Tuesday said it has received tentative approval from the US health regulator for its generic copy of allergic rhinitis Johnson & Johnson Consumer Inc's Zyrtec-D 12 Hour used for treating allergic rhinitis. The tentative nod by the US Food and Drug Administration (USFDA) is for the company's Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride extended-release tablets, 5 mg/120 mg, Unichem Laboratories said in a regulatory filing. The over the counter product is also indicated as a nasal decongestant. The product will be commercialised from Unichem's Goa plant on receipt of final approval, it added.